Published in PLoS One on September 04, 2009
Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res (2011) 1.60
Modulating the endocannabinoid system in human health and disease--successes and failures. FEBS J (2013) 1.59
Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10(-/-) mice by attenuating the activation of T cells and promoting their apoptosis. Toxicol Appl Pharmacol (2011) 1.05
Lack of effect of chronic pre-treatment with the FAAH inhibitor URB597 on inflammatory pain behaviour: evidence for plastic changes in the endocannabinoid system. Br J Pharmacol (2012) 0.93
High tumour cannabinoid CB1 receptor immunoreactivity negatively impacts disease-specific survival in stage II microsatellite stable colorectal cancer. PLoS One (2011) 0.93
Experimental colitis in mice is attenuated by changes in the levels of endocannabinoid metabolites induced by selective inhibition of fatty acid amide hydrolase (FAAH). J Crohns Colitis (2014) 0.92
Immunofluorescent spectral analysis reveals the intrathecal cannabinoid agonist, AM1241, produces spinal anti-inflammatory cytokine responses in neuropathic rats exhibiting relief from allodynia. Brain Behav (2012) 0.90
Topical and systemic cannabidiol improves trinitrobenzene sulfonic acid colitis in mice. Pharmacology (2012) 0.89
Inhibiting fatty acid amide hydrolase normalizes endotoxin-induced enhanced gastrointestinal motility in mice. Br J Pharmacol (2012) 0.89
N-Acylethanolamine-hydrolyzing acid amidase inhibition increases colon N-palmitoylethanolamine levels and counteracts murine colitis. FASEB J (2014) 0.87
Anandamide attenuates Th-17 cell-mediated delayed-type hypersensitivity response by triggering IL-10 production and consequent microRNA induction. PLoS One (2014) 0.87
Differential effects of CB(1) neutral antagonists and inverse agonists on gastrointestinal motility in mice. Neurogastroenterol Motil (2010) 0.87
Alternative targets within the endocannabinoid system for future treatment of gastrointestinal diseases. Can J Gastroenterol (2011) 0.85
Plasticity of mouse enteric synapses mediated through endocannabinoid and purinergic signaling. Neurogastroenterol Motil (2012) 0.82
Distribution and function of the endocannabinoid system in the rat and human bladder. Int Urogynecol J (2012) 0.82
Cannabis finds its way into treatment of Crohn's disease. Pharmacology (2013) 0.81
Ulcerative colitis impairs the acylethanolamide-based anti-inflammatory system reversal by 5-aminosalicylic acid and glucocorticoids. PLoS One (2012) 0.80
Inhibiting endocannabinoid biosynthesis: a novel approach to the treatment of constipation. Br J Pharmacol (2015) 0.80
Role of Cannabinoids in Gastrointestinal Mucosal Defense and Inflammation. Curr Neuropharmacol (2016) 0.80
The Role of the Endocannabinoid System in the Brain-Gut Axis. Gastroenterology (2016) 0.78
IBD: Patients with IBD find symptom relief in the Cannabis field. Nat Rev Gastroenterol Hepatol (2013) 0.78
Increased expression of cannabinoid CB₁ receptors in Achilles tendinosis. PLoS One (2011) 0.77
The gastrointestinal tract - a central organ of cannabinoid signaling in health and disease. Neurogastroenterol Motil (2016) 0.77
Cocaine-induced behavioral sensitization is associated with changes in the expression of endocannabinoid and glutamatergic signaling systems in the mouse prefrontal cortex. Int J Neuropsychopharmacol (2014) 0.76
Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go? Expert Rev Gastroenterol Hepatol (2017) 0.75
Therapeutic Use of Cannabis in Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y) (2016) 0.75
Cannabis and Pediatric Inflammatory Bowel Disease: Change Blossoms A Mile High. J Pediatr Gastroenterol Nutr (2016) 0.75
Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J (1955) 19.22
Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 13.45
Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol (1995) 8.09
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut (2006) 8.08
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med (1987) 7.73
Inflammatory bowel disease: cause and immunobiology. Lancet (2007) 6.07
Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A (2002) 5.33
Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol (2003) 3.60
The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci (2000) 3.41
Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem (2003) 2.75
The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest (2004) 2.52
Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain (1998) 2.43
Molecular characterization of human and mouse fatty acid amide hydrolases. Proc Natl Acad Sci U S A (1997) 2.25
Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway. J Biol Chem (2006) 2.09
Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry (2006) 2.01
Cannabinoids and the gastrointestinal tract. Gut (2001) 1.81
Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol (2001) 1.67
Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals. Eur J Pharmacol (1997) 1.61
Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology (2007) 1.59
Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology (2005) 1.47
Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology (2002) 1.41
Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J (2006) 1.36
Effects of cannabinoid receptor-2 activation on accelerated gastrointestinal transit in lipopolysaccharide-treated rats. Br J Pharmacol (2004) 1.33
Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia (2007) 1.33
Structural abnormalities of the nervous system in Crohn's disease and ulcerative colitis. Neurogastroenterol Motil (1998) 1.29
Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol (2007) 1.29
The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract. J Mol Med (Berl) (2005) 1.25
Immunohistochemical description of the endogenous cannabinoid system in the rat cerebellum and functionally related nuclei. J Comp Neurol (2008) 1.25
Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors. J Mol Med (Berl) (2008) 1.19
Biosynthetic pathways of the endocannabinoid anandamide. Chem Biodivers (2007) 1.18
Review article: endocannabinoids and their receptors in the enteric nervous system. Aliment Pharmacol Ther (2005) 1.15
Cannabinoids for gastrointestinal diseases: potential therapeutic applications. Expert Opin Investig Drugs (2003) 1.13
Fatty acid amide hydrolase controls mouse intestinal motility in vivo. Gastroenterology (2005) 1.12
2-Arachidonoylglycerol and the cannabinoid receptors. Chem Phys Lipids (2000) 1.10
Endocannabinoid overactivity and intestinal inflammation. Gut (2006) 1.06
The endocannabinoid signaling system: pharmacological and therapeutic aspects. Pharmacol Biochem Behav (2005) 1.04
The gastrointestinal pharmacology of cannabinoids. Curr Opin Pharmacol (2001) 0.98
Effect of cannabinoids on neural transmission in rat gastric fundus. Can J Physiol Pharmacol (2002) 0.98
Differential distribution of functional cannabinoid CB1 receptors in the mouse gastroenteric tract. Eur J Pharmacol (2003) 0.96
Evidence for the involvement of infectious agents in the pathogenesis of Crohn's disease. World J Gastroenterol (2008) 0.95
Distribution and function of monoacylglycerol lipase in the gastrointestinal tract. Am J Physiol Gastrointest Liver Physiol (2008) 0.89
Pharmacological characterisation of cannabinoid receptors inhibiting interleukin 2 release from human peripheral blood mononuclear cells. Eur J Pharmacol (2003) 0.86
A role for the endogenous cannabinoid system in the peripheral control of pain initiation. Prog Brain Res (2000) 0.84
Endocannabinoids and the gut. Prostaglandins Leukot Essent Fatty Acids (2002) 0.82
Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med (2012) 7.18
The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell (2011) 4.79
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med (2012) 3.44
Isolation and in vitro expansion of human colonic stem cells. Nat Med (2011) 3.20
Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. Cancer Cell (2012) 2.94
Identification of Lynch syndrome among patients with colorectal cancer. JAMA (2012) 2.77
A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci (2002) 2.52
EphB-ephrin-B interactions suppress colorectal cancer progression by compartmentalizing tumor cells. Nat Genet (2007) 2.33
Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology. J Mol Diagn (2006) 2.11
The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer (2008) 2.08
5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology (2010) 1.71
Performance of different microsatellite marker panels for detection of mismatch repair-deficient colorectal tumors. J Natl Cancer Inst (2007) 1.70
Nodal yield, morbidity, and recurrence after central neck dissection for papillary thyroid carcinoma. Surgery (2005) 1.64
Chromatin-bound IκBα regulates a subset of polycomb target genes in differentiation and cancer. Cancer Cell (2013) 1.61
The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol (2004) 1.58
Obesity-dependent cannabinoid modulation of proliferation in adult neurogenic regions. Eur J Neurosci (2011) 1.55
Risk of cancer in cases of suspected lynch syndrome without germline mutation. Gastroenterology (2013) 1.55
Risk of advanced proximal neoplasms according to distal colorectal findings: comparison of sigmoidoscopy-based strategies. J Natl Cancer Inst (2013) 1.47
Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. Gastroenterology (2010) 1.46
Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma. Clin Transl Oncol (2011) 1.46
Endosonographic and manometric evaluation of internal anal sphincter in patients with chronic anal fissure and its correlation with clinical outcome after topical glyceryl trinitrate therapy. Int J Colorectal Dis (2007) 1.39
Identification of MYH mutation carriers in colorectal cancer: a multicenter, case-control, population-based study. Clin Gastroenterol Hepatol (2007) 1.38
Key contribution of CPEB4-mediated translational control to cancer progression. Nat Med (2011) 1.37
Frequency of hereditary non-polyposis colorectal cancer and other colorectal cancer familial forms in Spain: a multicentre, prospective, nationwide study. Eur J Gastroenterol Hepatol (2004) 1.33
Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. J Clin Oncol (2013) 1.32
Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell. Cell Calcium (2006) 1.31
Aberrant gene promoter methylation associated with sporadic multiple colorectal cancer. PLoS One (2010) 1.25
Cannabinoid addiction: behavioral models and neural correlates. J Neurosci (2002) 1.24
A high degree of LINE-1 hypomethylation is a unique feature of early-onset colorectal cancer. PLoS One (2012) 1.24
Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol (2009) 1.23
Clinical performance of original and revised Bethesda guidelines for the identification of MSH2/MLH1 gene carriers in patients with newly diagnosed colorectal cancer: proposal of a new and simpler set of recommendations. Am J Gastroenterol (2006) 1.22
The epigenetic regulators Bmi1 and Ring1B are differentially regulated in pancreatitis and pancreatic ductal adenocarcinoma. J Pathol (2009) 1.22
A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening. Clin Gastroenterol Hepatol (2007) 1.20
Differential features of colorectal cancers fulfilling Amsterdam criteria without involvement of the mutator pathway. Clin Cancer Res (2005) 1.20
The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats. Neuropharmacology (2007) 1.16
Validation and extension of the PREMM1,2 model in a population-based cohort of colorectal cancer patients. Gastroenterology (2007) 1.16
Snail1 protein in the stroma as a new putative prognosis marker for colon tumours. PLoS One (2009) 1.16
Modifiable endoscopic factors that influence the adenoma detection rate in colorectal cancer screening colonoscopies. Gastrointest Endosc (2012) 1.15
Susceptibility genetic variants associated with colorectal cancer risk correlate with cancer phenotype. Gastroenterology (2010) 1.11
Postpolypectomy surveillance in patients with adenomas and serrated lesions: a proposal for risk stratification in the context of organized colorectal cancer-screening programs. Endoscopy (2014) 1.11
Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. Eur J Pharmacol (2006) 1.11
A prospective trial comparing wireless capsule endoscopy and barium contrast series for small-bowel surveillance in hereditary GI polyposis syndromes. Gastrointest Endosc (2005) 1.10
Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain. Pain (2007) 1.09
Vulvar angiomyxoma, aggressive angiomyxoma, and angiomyofibroblastoma: an immunohistochemical and ultrastructural study. Ultrastruct Pathol (2006) 1.05
Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole--LH 21. Neuropharmacology (2006) 1.02
Role of cannabinoid CB2 receptors in glucose homeostasis in rats. Eur J Pharmacol (2007) 1.01
A role for the putative cannabinoid receptor GPR55 in the islets of Langerhans. J Endocrinol (2011) 1.00
Relationship of colonoscopy-detected serrated polyps with synchronous advanced neoplasia in average-risk individuals. Gastrointest Endosc (2013) 1.00
Regulation of brain anandamide by acute administration of ethanol. Biochem J (2007) 0.99
Methylation analysis of MLH1 improves the selection of patients for genetic testing in Lynch syndrome. J Mol Diagn (2010) 0.98
The anandamide transport inhibitor AM404 reduces ethanol self-administration. Eur J Neurosci (2007) 0.98
Synchronous colorectal neoplasms in patients with colorectal cancer: predisposing individual and familial factors. Dis Colon Rectum (2004) 0.96
Anti-obesity efficacy of LH-21, a cannabinoid CB(1) receptor antagonist with poor brain penetration, in diet-induced obese rats. Br J Pharmacol (2012) 0.96
The role of the pancreatic endocannabinoid system in glucose metabolism. Best Pract Res Clin Endocrinol Metab (2009) 0.95
Oleylethanolamide impairs glucose tolerance and inhibits insulin-stimulated glucose uptake in rat adipocytes through p38 and JNK MAPK pathways. Am J Physiol Endocrinol Metab (2005) 0.95
Detection of metachronous neoplasms in colorectal cancer patients: identification of risk factors. Dis Colon Rectum (2007) 0.95
Adaptation to Spanish language and validation of the fecal incontinence quality of life scale. Dis Colon Rectum (2006) 0.94
Case-control study for colorectal cancer genetic susceptibility in EPICOLON: previously identified variants and mucins. BMC Cancer (2011) 0.93
A colorectal cancer genome-wide association study in a Spanish cohort identifies two variants associated with colorectal cancer risk at 1p33 and 8p12. BMC Genomics (2013) 0.91
Activation of the BMP4 pathway and early expression of CDX2 characterize non-specialized columnar metaplasia in a human model of Barrett's esophagus. J Gastrointest Surg (2011) 0.91
Pretreatment with subeffective doses of Rimonabant attenuates orexigenic actions of orexin A-hypocretin 1. Neuropharmacology (2007) 0.91
Epidemiological risk factors in microscopic colitis: a prospective case-control study. Inflamm Bowel Dis (2013) 0.91
Attenuation of cocaine-induced conditioned locomotion is associated with altered expression of hippocampal glutamate receptors in mice lacking LPA1 receptors. Psychopharmacology (Berl) (2011) 0.90
Single nucleotide polymorphisms in the Wnt and BMP pathways and colorectal cancer risk in a Spanish cohort. PLoS One (2010) 0.90
A genome-wide association study on a southern European population identifies a new Crohn's disease susceptibility locus at RBX1-EP300. Gut (2012) 0.90
[Clinical practice guideline. Prevention of colorectal cancer. 2009 update. Asociación Española de Gastroenterología]. Gastroenterol Hepatol (2009) 0.90
Oleoylethanolamide, a natural ligand for PPAR-alpha, inhibits insulin receptor signalling in HTC rat hepatoma cells. Biochim Biophys Acta (2009) 0.89
Association of the ARLTS1 Cys148Arg variant with sporadic and familial colorectal cancer. Carcinogenesis (2007) 0.89
Genetic susceptibility variants associated with colorectal cancer prognosis. Carcinogenesis (2013) 0.89
Expression of the cannabinoid system in muscle: effects of a high-fat diet and CB1 receptor blockade. Biochem J (2011) 0.89
Long-lasting increase of alcohol relapse by the cannabinoid receptor agonist WIN 55,212-2 during alcohol deprivation. J Neurosci (2004) 0.88
Oleoylethanolamide enhances β-adrenergic-mediated thermogenesis and white-to-brown adipocyte phenotype in epididymal white adipose tissue in rat. Dis Model Mech (2013) 0.88
Differential effects of single versus repeated alcohol withdrawal on the expression of endocannabinoid system-related genes in the rat amygdala. Alcohol Clin Exp Res (2011) 0.88
Cyclooxygenase 2 expression in colorectal cancer with DNA mismatch repair deficiency. Clin Cancer Res (2006) 0.87
Colorectal cancer prognosis twenty years later. World J Gastroenterol (2010) 0.87
Utility of p16 immunohistochemistry for the identification of Lynch syndrome. Clin Cancer Res (2009) 0.87
Diet-dependent modulation of hippocampal expression of endocannabinoid signaling-related proteins in cannabinoid antagonist-treated obese rats. Eur J Neurosci (2012) 0.86
Plasma visfatin concentrations in severely obese subjects are increased after intestinal bypass. Obesity (Silver Spring) (2007) 0.86
Evaluation of plasma-free endocannabinoids and their congeners in abstinent cocaine addicts seeking outpatient treatment: impact of psychiatric co-morbidity. Addict Biol (2013) 0.86
Effects of the endogenous PPAR-alpha agonist, oleoylethanolamide on MDMA-induced cognitive deficits in mice. Synapse (2010) 0.86
BMP2/BMP4 colorectal cancer susceptibility loci in northern and southern European populations. Carcinogenesis (2012) 0.86
Delphi consensus statement: Quality Indicators for Inflammatory Bowel Disease Comprehensive Care Units. J Crohns Colitis (2013) 0.85
Inhibition of specific NF-κB activity contributes to the tumor suppressor function of 14-3-3σ in breast cancer. PLoS One (2012) 0.85
Outcome in obscure gastrointestinal bleeding after capsule endoscopy. World J Gastrointest Endosc (2013) 0.85
Maternal deprivation has sexually dimorphic long-term effects on hypothalamic cell-turnover, body weight and circulating hormone levels. Horm Behav (2010) 0.84
Hyperactivity induced by the dopamine D2/D3 receptor agonist quinpirole is attenuated by inhibitors of endocannabinoid degradation in mice. Int J Neuropsychopharmacol (2012) 0.83
A truncated form of IKKα is responsible for specific nuclear IKK activity in colorectal cancer. Cell Rep (2012) 0.83
Effect of aspirin and antiplatelet drugs on the outcome of the fecal immunochemical test. Mayo Clin Proc (2013) 0.83
Elaidyl-sulfamide, an oleoylethanolamide-modelled PPARα agonist, reduces body weight gain and plasma cholesterol in rats. Dis Model Mech (2012) 0.83
High prevalence of serrated polyposis syndrome in FIT-based colorectal cancer screening programmes. Gut (2012) 0.82
GABAergic and cortical and subcortical glutamatergic axon terminals contain CB1 cannabinoid receptors in the ventromedial nucleus of the hypothalamus. PLoS One (2011) 0.82